(Q37939997)

25 August 2017

1 reference

title

Medical treatment of recurrent meningiomas (English)

1 reference

25 August 2017

Marc C Chamberlain

1

1 reference

25 August 2017

Jill S Barnholtz-Sloan

series ordinal

2

1 reference

25 August 2017

publication date

1 October 2011

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

25 August 2017

published in

1 reference

25 August 2017

volume

11

1 reference

25 August 2017

issue

10

1 reference

25 August 2017

page(s)

1425-1432

1 reference

The Lancet RADIATION-INDUCED HEAD AND NECK TUMOURS

25 August 2017

cites work

1 reference

Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis

21 January 2018

1 reference

High incidence of meningioma among Hiroshima atomic bomb survivors

21 January 2018

1 reference

Exogenous hormone use and meningioma risk: what do we tell our patients?

21 January 2018

1 reference

Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study

21 January 2018

1 reference

Association of meningioma with reproductive factors

21 January 2018

1 reference

Risk of brain tumors associated with exposure to exogenous female sex hormones.

21 January 2018

1 reference

Epidemiology and etiology of meningioma

21 January 2018

1 reference

Genomic landscape of meningiomas.

21 January 2018

1 reference

21 January 2018

1 reference

Meningioma: current treatment options and future directions

21 January 2018

1 reference

Medical therapies for meningiomas

21 January 2018

1 reference

21 January 2018

1 reference

Role of radiation therapy in treating intracranial meningiomas

21 January 2018

1 reference

Stereotactic radiation treatment for benign meningiomas

21 January 2018

1 reference

Advances in meningioma therapy

21 January 2018

1 reference

Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma.

21 January 2018

1 reference

A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study

21 January 2018

1 reference

Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice

21 January 2018

1 reference

Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas

21 January 2018

1 reference

Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea

21 January 2018

1 reference

Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up

21 January 2018

1 reference

Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma

21 January 2018

1 reference

Treatment of high risk or recurrent meningiomas with hydroxyurea

21 January 2018

1 reference

Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study

21 January 2018

1 reference

Non-resectable slow-growing meningiomas treated by hydroxyurea

21 January 2018

1 reference

High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma

21 January 2018

1 reference

Chronic suppressive therapy with calcium channel antagonists for refractory meningiomas

21 January 2018

1 reference

Temozolomide for treatment-resistant recurrent meningioma

21 January 2018

1 reference

Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas

21 January 2018

1 reference

Salvage chemotherapy with CPT-11 for recurrent meningioma

21 January 2018

1 reference

Adjuvant combined modality therapy for malignant meningiomas

21 January 2018

1 reference

A review of malignant meningiomas: diagnosis, characteristics, and treatment

21 January 2018

1 reference

Mitogenic signal transduction pathways in meningiomas: novel targets for meningioma chemotherapy?

21 January 2018

1 reference

Aberrant signaling pathways in meningiomas

21 January 2018

1 reference

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

21 January 2018

1 reference

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

21 January 2018

1 reference

A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.

21 January 2018

1 reference

Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study

21 January 2018

1 reference

Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity.

21 January 2018

1 reference

Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERN.11.38

1 reference

25 August 2017

1 reference